StockData
Repligen Corp logo

Repligen Corp (RGEN) stock

RGENNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 7/30132% above fair value
$162.18−0.60 (-0.37%)

Close on Nov 17, 2026Market cap $10.37BP/E –Yield –

Repligen cash

Cash and short-term investments held at the end of each period.

Repligen's cash was $862.98M at Sep 30, 2026. For fiscal 2025 it was $767.63M, up 1.4% from the year before. Over ten years it grew 30.3% a year on average. The highest annual figure on record is $767.63M in fiscal 2025.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$767.63M+1.4%
FY2024Dec 31, 2024$757.36M+0.8%
FY2023Dec 31, 2023$751.32M+43.5%
FY2022Dec 31, 2022$523.46M-13.3%
FY2021Dec 31, 2021$603.81M-15.8%
FY2020Dec 31, 2020$717.29M+33.5%
FY2019Dec 31, 2019$537.41M+177.3%
FY2018Dec 31, 2018$193.82M+11.5%
FY2017Dec 31, 2017$173.76M+41.6%
FY2016Dec 31, 2016$122.68M+124.9%
FY2015Dec 31, 2015$54.54M+54.2%
FY2014Dec 31, 2014$35.36M-42.6%
FY2013Dec 31, 2013$61.62M+24.2%
FY2011Mar 31, 2011$49.63M+296.2%
FY2010Mar 31, 2010$12.53M+148.5%
FY2009Mar 31, 2009$5.04M–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$862.98M+15.3%
Q2 FY2026Jun 30, 2026$810.45M+14.3%
Q1 FY2026Mar 31, 2026$784.53M+12.5%
Q4 FY2025Dec 31, 2025$767.63M+1.4%
Q3 FY2025Sep 30, 2025$748.75M-4.5%
Q2 FY2025Jun 30, 2025$708.86M-12.4%
Q1 FY2025Mar 31, 2025$697.23M-10.7%
Q4 FY2024Dec 31, 2024$757.36M+0.8%
Q3 FY2024Sep 30, 2024$783.96M+24.3%
Q2 FY2024Jun 30, 2024$809.15M+34.0%
Q1 FY2024Mar 31, 2024$780.62M+51.1%
Q4 FY2023Dec 31, 2023$751.32M+43.5%
Q3 FY2023Sep 30, 2023$630.78M+10.0%
Q2 FY2023Jun 30, 2023$603.66M+1.2%
Q1 FY2023Mar 31, 2023$516.61M-11.6%
Q4 FY2022Dec 31, 2022$523.46M-13.3%
Q3 FY2022Sep 30, 2022$573.36M-7.7%
Q2 FY2022Jun 30, 2022$596.51M-18.8%
Q1 FY2022Mar 31, 2022$584.64M-17.8%
Q4 FY2021Dec 31, 2021$603.81M-15.8%
Q3 FY2021Sep 30, 2021$621.10M+12.3%
Q2 FY2021Jun 30, 2021$734.33M+31.0%
Q1 FY2021Mar 31, 2021$711.32M+32.1%
Q4 FY2020Dec 31, 2020$717.29M+33.5%
Q3 FY2020Sep 30, 2020$553.30M+5.9%
Q2 FY2020Jun 30, 2020$560.36M+157.3%
Q1 FY2020Mar 31, 2020$538.57M+174.6%
Q4 FY2019Dec 31, 2019$537.41M+177.3%
Q3 FY2019Sep 30, 2019$522.43M+174.5%
Q2 FY2019Jun 30, 2019$217.82M+24.0%
Q1 FY2019Mar 31, 2019$196.14M+12.8%
Q4 FY2018Dec 31, 2018$193.82M+11.5%
Q3 FY2018Sep 30, 2018$190.30M+19.2%
Q2 FY2018Jun 30, 2018$175.61M+23.1%
Q1 FY2018Mar 31, 2018$173.88M+33.6%
Q4 FY2017Dec 31, 2017$173.76M+41.6%
Q3 FY2017Sep 30, 2017$159.67M–
Q2 FY2017Jun 30, 2017$142.66M–
Q1 FY2017Mar 31, 2017$130.11M–
Q4 FY2016Dec 31, 2016$122.68M–

More Repligen figures

See a number that looks wrong?